Lactocaseibacillus casei; chemotherapy; mucositis.
Mucositis in the gastrointestinal tract is an inflammation of the mucosa that has as one of the causes the administration of 5-Fluorouracil (5FU) in anticancer therapy. There is still no elucidated treatment for the cure or prophylaxis of mucositis. In this context, the present work's objective was to evaluate the effect of oral administration of Lactocaseibacilus casei (L. casei) in an animal model of intestinal mucositis. Initially, Lactocaseibacilus casei (1x109 CFU/mL) or saline was orally administered to Swiss mice starting 15 days before induction of mucositis by a single intraperitoneal administration of 5-FU (450mg/kg). After euthanasia, on day 18th, tissue samples from the colon and each segment of the small intestine were collected for histopathology. The jejunal tissues present iNOS and TNF-α immunoexpression, IL-1β, IL-6, and TNF-α levels, malondialdehyde (MDA) accumulation, and nuclear factor kappa B gene expression (NFkb-P65), toll receptor -like 4 (TLR-4), mucin-2 (MUC-2), occludin (OCLN) and zonula occludent-1 (ZO-1). L. casei reduced 5-FU-induced inflammation in the colon and small intestine (p<0.05), the levels of TNF-α, IL-1beta, IL-6 (p<0.05), and MDA (p< 0.05), as well as the expression of iNOS and TNF-α proteins (p<0.05). Furthermore, the gene expression of OCLN and ZO-1 was upregulated (p<0.05). In contrast, the gene expression of NFkb-P65 and TLR4 (p<0.05) was downregulated. The L.casei group also showed a higher population of lactic acid bacteria (p<0.05) compared to the control groups. Thus, the oral administration of L.casei demonstrated a potential protective effect against 5-FU-induced intestinal mucositis in Swiss mice.